United-Guardian, Inc. — Form 10-Q Summary
Reporting period: Three and nine months ended September 30, 2011; filed November 8, 2011. The company develops, manufactures and markets personal-care, pharmaceutical, medical and specialty industrial products.
Key financial results
| Metric | Q3 2011 | Q3 2010 | Nine months 2011 | Nine months 2010 |
|---|---|---|---|---|
| Net sales | $3.345 million | $3.848 million | $11.047 million | $11.160 million |
| Income from operations | $1.578 million | $1.800 million | $4.970 million | $4.125 million |
| Net income | $1.369 million | $1.244 million | $3.760 million | $2.964 million |
| Diluted EPS | $0.30 | $0.27 | $0.82 | $0.62 |
| Operating cash flow | Not separately reported | Not separately reported | $3.769 million | $3.057 million |
- Sales fell 13.1% in Q3 and 1.0% over nine months year over year. Cost of sales was 36.8% of sales in Q3 versus 37.7%; for the nine-month period it was 39.1% versus 38.2%.
- Cash and cash equivalents were $1.076 million and marketable securities were $10.658 million at September 30, 2011. Total current assets were $15.122 million, current liabilities $1.265 million, and working capital $13.857 million. The current ratio was 12.0:1.
- No borrowings or debt are listed on the balance sheet. Total assets were $16.442 million; stockholders’ equity was $15.166 million.
- Cash decreased $438,198 during the first nine months. Investing activities used $2.552 million, primarily reflecting net purchases of marketable securities; financing activities used $1.655 million, including dividends of $1.655 million ($0.36 per share).
Changes and operating drivers
- Q3 operating income declined 12.3% with lower sales; nine-month operating income rose 20.5%, partly because 2010 included an $847,744 charge for terminating the defined-benefit pension plan.
- Q3 net income increased 10.1%, while nine-month net income increased 26.8%. The 2011 results include $385,182 received in a supplier damage settlement, recognized in Q3, and a $18,251 net gain on asset sales for the nine months. These items make reported earnings less representative of underlying operations.
- Personal-care sales declined 14.2% in Q3 but increased 1.4% for nine months. Nine-month sales to the largest marketing partner, now Ashland Specialty Ingredients, rose 8.9%; weakness from partners in France, South Korea and Italy partly offset that increase.
- Pharmaceutical sales declined 41.4% in Q3 and 18.5% for nine months, mainly due to RENACIDIN production interruptions from November 2010 to May 2011 and customer inventory timing after a June price increase. Medical-product sales increased 22.0% in Q3 and 16.2% for nine months, driven by two customers.
- Nine-month investment income fell 29.5%, primarily reflecting lower interest rates and investment returns. Operating expenses decreased 8.6% over nine months.
Outlook, risks and other matters
- Management said working capital should support operating requirements for at least the next 12 months and did not expect significant capital expenditures for the remainder of 2011. No numerical earnings or revenue guidance was provided.
- The company expects to use cash for dividends, marketable securities and other opportunities it considers beneficial. It reported no off-balance-sheet arrangements and no legal proceedings.
- Risks identified include competition and product acceptance, product development, supplier/product quality and availability, regulation, intellectual-property changes, economic conditions, interest rates and securities-market conditions. RENACIDIN’s supplier disruption and reliance on marketing partners are notable operating exposures. The largest personal-care marketing partner was acquired by Ashland; management did not expect the change to harm the relationship.
- Management judged disclosure controls effective and reported no material change in internal control over financial reporting. The filing states there were no unrecognized tax benefits; tax years 2008–2010 remained subject to IRS and New York State examination.
Important facts for investors to verify
- How much of the earnings increase reflects recurring operations versus the $385,182 supplier settlement and the prior-year pension-termination charge.
- Whether RENACIDIN production and sales returned to historical levels after the supplier interruption and customer inventory effects.
- Sales trends and customer/partner concentration, including ongoing performance under Ashland Specialty Ingredients and demand from the two medical-product customers.
- Portfolio composition, liquidity and valuation of the $10.658 million in marketable securities, and the effect of continuing raw-material cost increases.